Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s Chief Executive Officer Norman Schwartz ...

Fintel reports that on December 7, 2023, UBS initiated coverage of Bio-Rad Laboratories Inc. - (NYSE:BIO) with a Buy recommendation. As of November 27, 2023, the average one-year price target for ...

Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...

insights from industryDr Chelsea PrattBiopharma Segment Marketing ManagerBio-Rad Laboratories In this interview, NewsMedical speaks to Dr Chelsea Pratt about Accurately quantifying AAV capsids ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year of ...

Aug 1 (Reuters) - Bio-Rad Laboratories (BIO.N), opens new tab cut its annual revenue growth forecast on Thursday, dragged down by weak demand for clinical diagnostics products from biotech clients.

Chief Operating Officer Jon DiVincenzo stated that Bio-Rad met its revised 2024 guidance for revenue and operating margin, achieving gross margin expansion through manufacturing productivity ...

Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chief Executive Officer Norman Schwartz, ...

Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and ...

Sumitomo Mitsui Trust Group Inc. lessened its position in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing ...

The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP and Currency-Neutral ...